Stay updated on Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The footer’s displayed ClinicalTrials.gov revision changes from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-10-31T17:03:02.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    A banner announces changes to NIH websites and says agencies are using “Super Intelligence” instead of “Artificial Intelligence” during the transition.
    Difference
    0.8%
    Check dated 2026-10-24T19:53:16.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The site revision changed from v3.7.1 to v3.7.2; the study record content remains unchanged.
    Difference
    0.1%
    Check dated 2026-10-17T20:37:35.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The site revision identifier changed from v3.7.0 to v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-10T20:50:00.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    A new revision entry v3.7.0 was added to the study record history, and the previous revision v3.6.6 was removed. This reflects standard version-tracking activity on the record rather than changes to the study content.
    Difference
    0.1%
    Check dated 2026-09-19T22:06:58.000Z thumbnail image
  6. Check
    66 days ago
    Change Detected
    Summary
    A new revision entry v3.6.6 was added to the record history, while the previous v3.6.5 entry was removed.
    Difference
    0.1%
    Check dated 2026-08-29T19:18:17.000Z thumbnail image

Stay in the know with updates to Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page.